Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
Özge Saatci, Rashedul Alam, Kim‐Tuyen Huynh‐Dam…·Özgür Şahin
This study identifies LINC00152 as a driver of tamoxifen resistance in ER+ breast cancer by inhibiting ferroptosis, and shows that targeting LINC00152 restores sensitivity to tamoxifen.